Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Surface Oncology, Inc. (SURF)

1.0001   0 (0.01%) 11-28 10:07
Open: 0.99 Pre. Close: 1
High: 1.0099 Low: 0.99
Volume: 12,751 Market Cap: 61(M)

Technical analysis

as of: 2022-11-28 9:52:38 AM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.44     One year: 1.67
Support: Support1: 0.92    Support2: 0.76
Resistance: Resistance1: 1.23    Resistance2: 1.42
Pivot: 1.04
Moving Average: MA(5): 0.99     MA(20): 1.09
MA(100): 1.38     MA(250): 2.38
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 10.1     %D(3): 8.9
RSI: RSI(14): 42.1
52-week: High: 5.98  Low: 0.92
Average Vol(K): 3-Month: 334 (K)  10-Days: 211 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SURF ] has closed above bottom band by 30.3%. Bollinger Bands are 33.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.02 - 1.03 1.03 - 1.04
Low: 0.96 - 0.97 0.97 - 0.98
Close: 0.99 - 1 1 - 1.01

Company Description

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Headline News

Mon, 28 Nov 2022
Delaware State Parks start selling 2023 surf-fishing permits Tuesday - The News Journal

Mon, 28 Nov 2022
Surfing the Gales of November - WDIO

Mon, 28 Nov 2022
The Surf Signature RV Resort to Host a Grand Opening Event On November 30, 2022 - SRQ Daily Nov 28, 2022 - SRQ Magazine

Sun, 27 Nov 2022
Catching Up with 2x Longboard World Champ Soleil Errico -

Sun, 27 Nov 2022
“Getting Youngsters Who Know How to Surf but Can’t Swim”: Laird Hamilton Draws a Critical View of the Evolution of Surfing - EssentiallySports

Sun, 27 Nov 2022
Stab Recommends: Solite's Custom-Fitting Surf Booties - Stab Magazine

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 61 (M)
Shares Float 52 (M)
% Held by Insiders 0.6 (%)
% Held by Institutions 53.6 (%)
Shares Short 1,390 (K)
Shares Short P.Month 1,650 (K)

Stock Financials

EPS -1.24
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.86
Profit Margin (%) -219.9
Operating Margin (%) -212.5
Return on Assets (ttm) -21.7
Return on Equity (ttm) -54.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.85
Sales Per Share 0.49
EBITDA (p.s.) -1.04
Qtrly Earnings Growth 0
Operating Cash Flow -54 (M)
Levered Free Cash Flow -30 (M)

Stock Valuations

PE Ratio -0.81
PEG Ratio 0
Price to Book value 0.53
Price to Sales 1.98
Price to Cash Flow -1.12

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.